Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn's disease and ulcerative colitis in the United States.
Advanced therapy
Biologics
Claims-based algorithm
Crohn’s disease
HealthCore Integrated Research Database®
Inadequate response
Inflammatory bowel disease
Tumor necrosis factor inhibitors/TNFi
Ulcerative colitis
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
09 Mar 2023
09 Mar 2023
Historique:
received:
03
03
2022
accepted:
13
02
2023
entrez:
9
3
2023
pubmed:
10
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
The purpose of this analysis was to assess the frequency of inadequate response over 1 year from advanced therapy initiation among patients with Crohn's disease (CD) or ulcerative colitis (UC) in the United States using a claims-based algorithm. Factors associated with inadequate response were also analyzed. This study utilized claims data of adult patients from the HealthCore Integrated Research Database (HIRD A total of 2437 patients with CD and 1692 patients with UC were included in this analysis. In patients with CD (mean age: 41 years; female: 53%), 81% had initiated TNFi, and 62% had inadequate response. In patients with UC (mean age: 42 years; female: 48%), 78% had initiated a TNFi, and 63% had an inadequate response. In both patients with CD and UC, inadequate response was associated with low adherence (CD: 41%; UC: 42%). Inadequate responders were more likely to be prescribed a TNFi (for CD: odds ratio [OR] = 1.94; p < 0.001; for UC: OR = 2.76; p < 0.0001). More than 60% of patients with CD or UC had an inadequate response to their index advanced therapy within 1 year after initiation, mostly driven by low adherence. This modified claims-based algorithm for CD and UC appears useful to classify inadequate responders in health plan claims data.
Sections du résumé
BACKGROUND
BACKGROUND
The purpose of this analysis was to assess the frequency of inadequate response over 1 year from advanced therapy initiation among patients with Crohn's disease (CD) or ulcerative colitis (UC) in the United States using a claims-based algorithm. Factors associated with inadequate response were also analyzed.
METHODS
METHODS
This study utilized claims data of adult patients from the HealthCore Integrated Research Database (HIRD
RESULTS
RESULTS
A total of 2437 patients with CD and 1692 patients with UC were included in this analysis. In patients with CD (mean age: 41 years; female: 53%), 81% had initiated TNFi, and 62% had inadequate response. In patients with UC (mean age: 42 years; female: 48%), 78% had initiated a TNFi, and 63% had an inadequate response. In both patients with CD and UC, inadequate response was associated with low adherence (CD: 41%; UC: 42%). Inadequate responders were more likely to be prescribed a TNFi (for CD: odds ratio [OR] = 1.94; p < 0.001; for UC: OR = 2.76; p < 0.0001).
CONCLUSION
CONCLUSIONS
More than 60% of patients with CD or UC had an inadequate response to their index advanced therapy within 1 year after initiation, mostly driven by low adherence. This modified claims-based algorithm for CD and UC appears useful to classify inadequate responders in health plan claims data.
Identifiants
pubmed: 36894911
doi: 10.1186/s12876-023-02675-w
pii: 10.1186/s12876-023-02675-w
pmc: PMC9996947
doi:
Substances chimiques
Immunologic Factors
0
Biological Products
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Informations de copyright
© 2023. The Author(s).
Références
Clin Ther. 2018 Sep;40(9):1509-1521.e5
pubmed: 30126706
Clin Gastroenterol Hepatol. 2014 May;12(5):811-817.e3
pubmed: 23811254
Value Health. 2017 Jun;20(6):752-761
pubmed: 28577692
MMWR Morb Mortal Wkly Rep. 2016 Oct 28;65(42):1166-1169
pubmed: 27787492
Curr Opin Gastroenterol. 2019 Jul;35(4):302-310
pubmed: 30973355
Inquiry. 2019 Jan-Dec;56:46958019887816
pubmed: 31744340
J Health Econ Outcomes Res. 2018 Sep 01;6(1):96-112
pubmed: 32685575
Clin Pharmacokinet. 2005;44(1):61-98
pubmed: 15634032
Clin Rheumatol. 2022 Sep;41(9):2863-2874
pubmed: 35672618
Am J Med. 1977 Aug;63(2):200-7
pubmed: 888843
Intest Res. 2017 Oct;15(4):434-445
pubmed: 29142511
Inflamm Bowel Dis. 2021 Jul 27;27(8):1177-1183
pubmed: 33043982
Inflamm Bowel Dis. 2022 Nov 2;28(11):1647-1657
pubmed: 35134912
Autoimmun Rev. 2014 Jan;13(1):24-30
pubmed: 23792214
Drugs. 1995 Aug;50(2):317-33
pubmed: 8521761
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
Arthritis Res Ther. 2011;13(5):R155
pubmed: 21933396
Clin Gastroenterol Hepatol. 2015 Jul;13(7):1293-1301.e5; quiz e70, e72
pubmed: 25724699
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30
pubmed: 31648971
PLoS One. 2020 Jan 16;15(1):e0227914
pubmed: 31945774
N Engl J Med. 2010 Sep 9;363(11):1086-7; author reply 1087-8
pubmed: 20848681
Am J Gastroenterol. 2018 Apr;113(4):481-517
pubmed: 29610508